Elevated plasma big ET‐1 is associated with distant failure in patients with advanced‐stage nasopharyngeal carcinoma

Endothelin‐1 (ET‐1) is a potent vasoactive peptide and a hypoxia‐inducible angiogenic growth factor associated with the development and spread of solid tumors. The clinical significance of plasma big ET‐1 in patients with advanced‐stage nasopharyngeal carcinoma (NPC) is not known.

[1]  T. Mok,et al.  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. , 2005, Journal of the National Cancer Institute.

[2]  J. Berkhof,et al.  The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. London,et al.  Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. , 2004, The International journal of biological markers.

[4]  Jin-Ching Lin,et al.  Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate? , 2004, International journal of radiation oncology, biology, physics.

[5]  Jun Ma,et al.  Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Sham,et al.  Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Elahi,et al.  Prognosis of colorectal cancer patients with elevated endothelin-1 concentrations. , 2004, Asian journal of surgery.

[8]  J. Chirgwin,et al.  A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Nelson,et al.  The endothelin axis: emerging role in cancer , 2003, Nature Reviews Cancer.

[11]  I. Taylor,et al.  Endothelin-1: a multifunctional molecule in cancer , 2003, British Journal of Cancer.

[12]  Jun Ma,et al.  Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? , 2001, International journal of radiation oncology, biology, physics.

[13]  Jun Ma,et al.  Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Uggeri,et al.  Effects of Oncological Surgery on Endothelin-1 Secretion in Patients with Operable Gastric Cancer , 2000, The International journal of biological markers.

[15]  P. Johnson,et al.  Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. , 1999, International journal of radiation oncology, biology, physics.

[16]  S. Thongprasert,et al.  Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Associati , 1998 .

[17]  S. Thongprasert,et al.  Preliminary report of the asian‐oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma , 1998, Cancer.

[18]  K. Catt,et al.  Endothelins as Autocrine Regulators of Tumor Cell Growth , 1998, Trends in Endocrinology & Metabolism.

[19]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Vumca I Trial.  Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. , 1996, International journal of radiation oncology, biology, physics.

[21]  F. Eschwège,et al.  Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. , 1995, International journal of radiation oncology, biology, physics.

[22]  G. Ahlborg,et al.  Metabolism of Big endothelin-1 (1–38) and (22–38) in the human circulation in relation to production of endothelin-1 (1–21) , 1995, Regulatory Peptides.

[23]  A. Seymour.  Histological Typing of Tumours of the Upper Respiratory Tract and Ear , 1991 .

[24]  M. Shichiri,et al.  Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. , 1991, The Journal of clinical investigation.

[25]  Y. Nakamura,et al.  Production of endothelin in human cancer cell lines. , 1990, Cancer research.

[26]  M. Yanagisawa,et al.  The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .